1 |
Clement DSVM, Leerdam MEV, de Jong S, Weickert MO, Ramage JK, Tesselaar MET, Srirajaskanthan R. Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours. Cancers (Basel) 2023;15. [PMID: 36765740 DOI: 10.3390/cancers15030782] [Reference Citation Analysis]
|
2 |
Sebastian-Valles F, Sánchez de la Blanca Carrero N, Rodríguez-Laval V, Martinez-Hernández R, Serrano-Somavilla A, Knott-Torcal C, Muñoz de Nova JL, Martín-Pérez E, Marazuela M, Sampedro-Nuñez MA. Impact of Change in Body Composition during Follow-Up on the Survival of GEP-NET. Cancers (Basel) 2022;14. [PMID: 36358607 DOI: 10.3390/cancers14215189] [Reference Citation Analysis]
|
3 |
Pavlidis ET, Pavlidis TE. Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update. World J Clin Cases 2022; 10(27): 9573-9587 [DOI: 10.12998/wjcc.v10.i27.9573] [Reference Citation Analysis]
|
4 |
Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers 2022;14:3231. [DOI: 10.3390/cancers14133231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|